Covid-19: Pfizer and Biotech has Set Their Eyes on US Approval For Children 5-11 Years Old
by Naba Batool
SHARES
Administration for the emergency use of their Covid-19 inoculations for children who fall in the age group of 5 to 11. This group of children currently has no available jabs for them.
UPDATE: We and @BioNTech_Group officially submitted our request to @US_FDA for Emergency Use Authorization (EUA) of our #COVID19 vaccine in children 5 to <12. pic.twitter.com/72Z2HXlkOx
— Pfizer Inc. (@pfizer) October 7, 2021
Continuing with the above-mentioned matter, the US Food, and Drug Administration has set a date of 26 October for this application approval. They will gather their panel to discuss this matter. Their pending decision is highly anticipated as it will decide the status of treatment of almost 28 million children around the globe.
According to an official tweet by Pfizer "With new cases in children in the U.S. continuing to be at a high level, this submission is an important step in our ongoing effort against #COVID19,"
It is pertinent to notice here that Pfizer is the leading vaccine provider for the age group of 12-15.
With this approval, millions of kids around the globe will be immunized against this deadly disease. The trials of the said vaccine have been successful in children from 5-11 years old. This authorization is much more important at this current moment because the schools are opening all around the globe.
The abovementioned renowned drug makers are also discovering ways to initiate immunizations in children from 6 months to 2 years of age. They have laid all the groundwork. With the help of approval, they will be able to provide vaccinations for this neglected population group.
